Renal cell carcinoma - The Lancet

Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma - eBioMedicine

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - The Lancet Oncology

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study - The Lancet

The multispeciality approach to the management of localised kidney cancer - The Lancet

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

BIONIKK: Results of the first randomized clinical trial based on molecular groups in metastatic renal cell carcinoma

Kidney Cancer Weill Cornell Medicine: Department of Urology - New York

Renal cell carcinoma Nature Reviews Disease Primers

The multispeciality approach to the management of localised kidney cancer - The Lancet

Renal cell carcinoma - The Lancet

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study - The Lancet Digital Health

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial - The Lancet Oncology